anmelden
Analysen von Richard Vosser
| 23.12.25 | Novartis Overweight | JP Morgan Chase & Co. | |
| 23.12.25 | Sanofi Neutral | JP Morgan Chase & Co. | |
| 23.12.25 | Roche Neutral | JP Morgan Chase & Co. | |
| 18.12.25 | Merck Overweight | JP Morgan Chase & Co. | |
| 16.12.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 15.12.25 | Merck Overweight | JP Morgan Chase & Co. | |
| 15.12.25 | arGEN-X Overweight | JP Morgan Chase & Co. | |
| 15.12.25 | Sanofi Neutral | JP Morgan Chase & Co. | |
|
Werbung
|
|||
| 15.12.25 | Sartorius Stedim Biotech Overweight | JP Morgan Chase & Co. | |
| 15.12.25 | Sartorius vz. Overweight | JP Morgan Chase & Co. | |
| 11.12.25 | Roche Neutral | JP Morgan Chase & Co. | |
| 08.12.25 | Sartorius Stedim Biotech Overweight | JP Morgan Chase & Co. | |
| 08.12.25 | Sartorius vz. Overweight | JP Morgan Chase & Co. | |
| 08.12.25 | Merck Overweight | JP Morgan Chase & Co. | |
| 08.12.25 | Sanofi Neutral | JP Morgan Chase & Co. | |
| 08.12.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 08.12.25 | Bayer Overweight | JP Morgan Chase & Co. | |
| 08.12.25 | Roche Neutral | JP Morgan Chase & Co. | |
| 08.12.25 | GSK Underweight | JP Morgan Chase & Co. | |
| 08.12.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 08.12.25 | Novartis Overweight | JP Morgan Chase & Co. | |
| 02.12.25 | Bayer Neutral | JP Morgan Chase & Co. | |
| 25.11.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 24.11.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 24.11.25 | Bayer Neutral | JP Morgan Chase & Co. | |
| 14.11.25 | Merck Overweight | JP Morgan Chase & Co. | |
| 13.11.25 | Merck Overweight | JP Morgan Chase & Co. | |
| 12.11.25 | Bayer Neutral | JP Morgan Chase & Co. | |
| 12.11.25 | Novartis Neutral | JP Morgan Chase & Co. | |
| 10.11.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 10.11.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 10.11.25 | Bayer Neutral | JP Morgan Chase & Co. | |
| 07.11.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 05.11.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.11.25 | Merck Overweight | JP Morgan Chase & Co. | |
| 03.11.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 30.10.25 | Merck Overweight | JP Morgan Chase & Co. | |
| 30.10.25 | Bayer Neutral | JP Morgan Chase & Co. | |
| 29.10.25 | Merck Overweight | JP Morgan Chase & Co. | |
| 28.10.25 | Novartis Neutral | JP Morgan Chase & Co. | |
| 27.10.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 24.10.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 24.10.25 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 23.10.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 22.10.25 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 20.10.25 | Novartis Neutral | JP Morgan Chase & Co. | |
| 20.10.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 20.10.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 17.10.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 17.10.25 | Sartorius vz. Overweight | JP Morgan Chase & Co. | |
